Syros Pharmaceuticals Inc. (NASDAQ: SYRS)’s stock price has dropped by -8.09 in relation to previous closing price of 5.56. Nevertheless, the company has seen a loss of -7.59% in its stock price over the last five trading days. Zacks Investment Research reported 2024-04-10 that The FDA bestows a Fast Track Designation to Syros’ (SYRS) pipeline candidate, tamibarotene, in combination with venetoclax and azacitidine to treat newly diagnosed acute myeloid leukemia. Stock rises.
Is It Worth Investing in Syros Pharmaceuticals Inc. (NASDAQ: SYRS) Right Now?
Additionally, the 36-month beta value for SYRS is 1.74. There are mixed opinions on the stock, with 3 analysts rating it as a “buy,” 2 rating it as “overweight,” 2 rating it as “hold,” and 0 rating it as “sell.”
The public float for SYRS is 18.42M and currently, short sellers hold a 9.89% ratio of that float. The average trading volume of SYRS on April 18, 2024 was 222.60K shares.
SYRS’s Market Performance
SYRS’s stock has seen a -7.59% decrease for the week, with a -16.23% drop in the past month and a -27.62% fall in the past quarter. The volatility ratio for the week is 10.03%, and the volatility levels for the past 30 days are at 8.97% for Syros Pharmaceuticals Inc. The simple moving average for the past 20 days is -7.85% for SYRS’s stock, with a 8.92% simple moving average for the past 200 days.
Analysts’ Opinion of SYRS
Many brokerage firms have already submitted their reports for SYRS stocks, with H.C. Wainwright repeating the rating for SYRS by listing it as a “Buy.” The predicted price for SYRS in the upcoming period, according to H.C. Wainwright is $15 based on the research report published on November 04, 2020 of the previous year 2020.
Alliance Global Partners, on the other hand, stated in their research note that they expect to see SYRS reach a price target of $18. The rating they have provided for SYRS stocks is “Buy” according to the report published on September 22nd, 2020.
SYRS Trading at -20.51% from the 50-Day Moving Average
After a stumble in the market that brought SYRS to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -37.45% of loss for the given period.
Volatility was left at 8.97%, however, over the last 30 days, the volatility rate increased by 10.03%, as shares sank -17.98% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -31.50% lower at present.
During the last 5 trading sessions, SYRS fell by -7.59%, which changed the moving average for the period of 200-days by +62.22% in comparison to the 20-day moving average, which settled at $5.49. In addition, Syros Pharmaceuticals Inc. saw -34.40% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at SYRS starting from Roth David, who sale 10,451 shares at the price of $4.95 back on Apr 03 ’24. After this action, Roth David now owns 0 shares of Syros Pharmaceuticals Inc., valued at $51,732 using the latest closing price.
Roth David, the Chief Medical Officer of Syros Pharmaceuticals Inc., sale 150 shares at $4.98 during a trade that took place back on Apr 02 ’24, which means that Roth David is holding 10,451 shares at $747 based on the most recent closing price.
Stock Fundamentals for SYRS
Current profitability levels for the company are sitting at:
- -12.97 for the present operating margin
- 0.77 for the gross margin
The net margin for Syros Pharmaceuticals Inc. stands at -15.67. The total capital return value is set at -0.98. Equity return is now at value -227.94, with -79.76 for asset returns.
Based on Syros Pharmaceuticals Inc. (SYRS), the company’s capital structure generated 0.72 points at debt to capital in total, while cash flow to debt ratio is standing at -2.52. The debt to equity ratio resting at 2.61. The interest coverage ratio of the stock is -51.11.
Currently, EBITDA for the company is -124.25 million with net debt to EBITDA at 0.63. When we switch over and look at the enterprise to sales, we see a ratio of 5.81. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.95.
Conclusion
In conclusion, Syros Pharmaceuticals Inc. (SYRS) has seen bad performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
